T-88 human monoclonal antibody data

The Emeryville, Calif., company said it was dropping development of the MAb after it failed to demonstrate a reduction in mortality in a Phase III trial of 826 patients at 34 centers in the U.S. No additional data will be released until the trial is published. ...